Cytokinetics Inc (CYTK) Stock Price & Analysis

Cytokinetics Inc (CYTK) rose 0.81% to USD 68.45 as of June 10, 2026 at 00:40 UTC, according to Nexqual real-time market data.

CYTK last closed at USD 67.9; the session ranged USD 66.88–70.33 on volume of 2,384,859 shares. Market capitalization is $9.29B, with a 52-week range of USD 31.99–80.2 (NMS). Source: Nexqual, June 10, 2026 at 00:40 UTC.

Key Statistics (as of June 10, 2026 at 00:40 UTC)

Technical Analysis (CYTK)

Nexqual's technical model rates CYTK "SELL" based on 1 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 00:40 UTC.

Analyst Ratings (CYTK)

Wall Street analysts rate CYTK "Buy" based on 20 analysts, with a mean price target of USD 104.7 (range USD 69–146), per Nexqual as of June 10, 2026 at 00:40 UTC.

Earnings (CYTK)

Recent Earnings History

Source: Nexqual, June 10, 2026 at 00:40 UTC.

Financials & Fundamentals (CYTK)

Source: Nexqual, June 10, 2026 at 00:40 UTC.

Financial Health Score (CYTK)

Nexqual rates Cytokinetics Inc's overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 00:40 UTC.

Ownership (CYTK)

Source: Nexqual, June 10, 2026 at 00:40 UTC.

Leadership (CYTK)

Cytokinetics Inc is led by Robert I. Blum (age 61), CEO, President & Director, per Nexqual as of June 10, 2026 at 00:40 UTC.

Major Backers & Investors (CYTK)

Notable institutional backers of Cytokinetics Inc include T. Rowe Price, FMR, LLC, Wellington Management, according to Nexqual as of June 10, 2026 at 00:40 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, June 10, 2026 at 00:40 UTC.

From Cytokinetics Inc's Latest SEC 10-K Filing (filed 2026-02-26)

Key Strengths & Strategy (as disclosed to the SEC)

• Our market research supports our belief that MYQORZO will be highly competitive amongst cardiac myosin inhibitors, potentially eventually achieving a greater than 50% market share in the United States but also growing the cardiac myosin inhibitor category overall.
• Finally, in January 2026 we submitted a supplemental NDA for MYQORZO to the FDA requesting to include the results of MAPLE-HCM, a Phase 3 randomized, double blind, active-comparator clinical trial of aficamten as monotherapy compared to metoprolol as a monotherapy in patients with obstructive HCM, in the label.
• We submitted a supplemental NDA to the FDA in January 2026 with the intent to include the results of MAPLE-HCM (a Phase 3 randomized, double blind, active-comparator clinical trial of aficamten as monotherapy compared to metoprolol as a monotherapy in patients with obstructive HCM) in the label.
• The FDA granted aficamten orphan drug designation for the treatment of symptomatic HCM in 2021.

Partnerships

• Collaboration for Commercialization of Aficamten in Japan We are party to a collaboration and license agreement with Bayer Consumer Care AG, an affiliate of Bayer AG, for the exclusive development and commercialization of drug products containing aficamten in Japan, subject to certain reserved development rights of Cytokinetics to conduct ACACIA-HCM and CEDAR-HCM in Japan.
• Royalty Pharma Revenue Interest We are party to a revenue interest agreement with RPI ICAV, the RP Aficamten RPA, pursuant to which RPI ICAV purchased rights to certain revenue streams from net sales of MYQORZO and any other future potential pharmaceutical products containing aficamten by us, our affiliates and our licensees.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 00:40 UTC. This page is informational and not investment advice.